Asceneuron researches and develops oral small molecule therapeutics targeting tauopathies for treating progressive supranuclear palsy (PSP), other related neurodegenerative diseases and Alzheimer’s disease. The lead product, an O-GlcNAcase inhibitor that in preclinical studies has been demonstrated to modulate tau pathology, has entered the critical regulatory studies to allow its entry into human clinical testing. Neuronal deposits of the microtubule-associated tau protein are a common feature of tauopathies and known to be a major contributor to neurodegenerative diseases.

Biopharmaceuticals